Investing in RxSight shares carries several notable risks typical of commercial-stage medical technology and biotechnology enterprises. Key vulnerabilities include potential adoption hurdles among ophthalmology practices, slower-than-expected revenue growth, competitive pressures from alternative premium intraocular lens manufacturers, and ongoing regulatory or compliance scrutiny. Furthermore, small-cap medical equities frequently experience high stock price volatility, sensitivity to broader healthcare sector shifts, and potential legal exposure from shareholder lawsuits triggered by downward revisions to quarterly financial guidance. Thorough fundamental analysis and diversification are essential risk-management steps.